Edwards Stephanie, Fitzgerald Lisa, Mutch Allyson, Dean Judith A, Ford Pauline, Howard Chris, Watts Peter, Gartner Coral
The University of Queensland, Faculty of Medicine, School of Public Health, The Public Health Building, Corner of Wyndham St and Herston Road, Herston QLD 4006, Australia.
The University of Queensland, Faculty of Health and Behavioural Sciences, School of Dentistry, Oral Health Centre, 288 Herston Road, Herston QLD 4006, Australia.
Int J Drug Policy. 2021 Nov;97:103349. doi: 10.1016/j.drugpo.2021.103349. Epub 2021 Jul 10.
People living with HIV (PLHIV) have a higher rate of smoking and experience a greater burden of tobacco-related disease than the general population. This study aimed to understand the role smoking plays in the lives of PLHIV, participants' views of traditionally available nicotine products (e.g., nicotine replacement therapy or NRT) and novel nicotine products (e.g., nicotine vaping products or NVPs) as both short-term quit aids and long-term substitutes for cigarettes.
Semi-structured focus groups were conducted with PLHIV who smoked. Focus groups were transcribed and analysed using a combination of deductive and inductive thematic analysis. A brief questionnaire of nicotine product use and interest was also completed and the quantitative data presented using descriptive statistics.
Fifty-four participants took part in 11 focus groups. Participants' views of smoking, quitting and nicotine products were diverse. Commitment to smoking and interest in quitting were categorised into three groups across a smoking-quitting continuum: committed to smoking, ambivalent about smoking and reluctantly smoking. NRT was criticised for a range of side effects and primarily considered as a short-term cessation aid. NVPs generated debate. NVPs that closely resembled cigarettes were viewed as the most acceptable product and were considered to be more suitable than NRT for long-term use.
Understanding the unique needs, goals and views of PLHIV related to smoking, quitting smoking and using nicotine products could inform development of novel and tailored smoking interventions for PLHIV. NVPs should be further examined as potential long-term substitutes for PLHIV who are ambivalent about smoking. However, traditional smoking cessation assistance (approved cessation aids and counselling) is likely to be most appropriate for PLHIV who are reluctantly smoking.
与普通人群相比,人类免疫缺陷病毒感染者(PLHIV)吸烟率更高,且承受着更重的烟草相关疾病负担。本研究旨在了解吸烟在PLHIV生活中所起的作用、参与者对传统可用尼古丁产品(如尼古丁替代疗法或NRT)以及新型尼古丁产品(如尼古丁雾化产品或NVPs)作为短期戒烟辅助工具和香烟长期替代品的看法。
对吸烟的PLHIV进行半结构化焦点小组访谈。焦点小组访谈内容经转录后,采用演绎和归纳主题分析相结合的方法进行分析。还完成了一份关于尼古丁产品使用和兴趣的简短问卷,并使用描述性统计呈现定量数据。
54名参与者参加了11个焦点小组。参与者对吸烟、戒烟和尼古丁产品的看法各不相同。在吸烟-戒烟连续体上,对吸烟的执着程度和戒烟意愿被分为三组:坚持吸烟、对吸烟矛盾纠结、勉强吸烟。NRT因一系列副作用受到批评,主要被视为短期戒烟辅助工具。NVPs引发了争议。与香烟极为相似的NVPs被视为最可接受的产品,且被认为比NRT更适合长期使用。
了解PLHIV在吸烟、戒烟和使用尼古丁产品方面的独特需求、目标和看法,可为开发针对PLHIV的新型定制化吸烟干预措施提供参考。对于对吸烟矛盾纠结的PLHIV,应进一步研究NVPs作为潜在长期替代品的可能性。然而,传统的戒烟援助(经批准的戒烟辅助工具和咨询)可能最适合勉强吸烟的PLHIV。